critical COVID-19 patient – Page 3 – Communicable Diseases Research

The effect of high-dose parenteral vitamin D 3 on COVID-19-related inhospital mortality in critical COVID-19 patients during intensive care unit admission: an observational cohort study

Observational Study

Published on 2021-09-012022-10-05
Journal: European journal of clinical nutrition [Category] SARS, 임상, 진단, 치료기술, 치료법,

Genome-wide association study of COVID-19 severity among the Chinese population

Article

Published on 2021-08-312022-10-04
Journal: Cell Discovery [Category] 유전자 메커니즘, 임상,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome Asian association C11orf71 CADM1 cause China Chinese chromosome Clinical treatment Cohort complex interaction components controls coronavirus coronavirus disease COVID-19 COVID-19 cohort COVID-19 severity critical COVID-19 patient CTSC disease eQTL Genetic genetic determinant Genome-wide association studies Genome-wide association study highlight hospital hospitals Host Infection loci Meta-analysis microbial Mild moderate NNMT Odds ratio Pathogenesis Patient performed Population Population genetics REXO2 SARS-CoV-2 severity of COVID-19 significantly susceptibility union Wuhan
[DOI] 10.1038/s41421-021-00318-6 PMC 바로가기 [Article Type] Article

Effectiveness of Pulmonary Rehabilitation in Severe and Critically Ill COVID-19 Patients: A Controlled Study

Article

Published on 2021-08-252022-10-29
Journal: International Journal of Environmental Research an [Category] COVID-19, MERS, SARS,

Elevated Pancreatic Enzymes in ICU Patients With COVID-19 in Wuhan, China: A Retrospective Study

Medicine

Published on 2021-08-172022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] addition Admission All participant amylase Analysis baseline characteristics caused Complication conditions cough COVID-19 COVID-19 patient COVID-19 patients critical COVID-19 patient Degradation discharge elevated enrolled enzyme Enzymes Fever hospital ICU incidence Increased information Injury intensive care Kidney injury life threatening Lipase Logistic management mechanical ventilation medical resource Mortality multiple organ failure multivariable myalgia no statistical difference Odds ratio Oxygenation pancreas pancreatic pancreatic enzyme pancreatic enzymes Pancreatitis pandemic Patient patients patients with COVID-19 poor prognosis progressed reported risk factor Symptom Treatment Wuhan
[DOI] 10.3389/fmed.2021.663646 PMC 바로가기 [Article Type] Medicine

Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients

SARS-CoV-2에 대한 체액성 면역의 동적 지형 매핑은 중요한 COVID-19 환자의 생존과 관련된 비구조적 단백질 항체를 식별합니다

Article

Published on 2021-08-172022-09-10
Journal: Signal Transduction and Targeted Therapy [Category] MERS, SARS, 바이오마커, 임상, 진단, 치료기술, 치료법, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis antibody Antibody Response Antibody responses binding epitope clinical variable clinical variables Cohort comprehensive analysis coronavirus correlation COVID-19 COVID-19 pathogenesis COVID-19 severity Critical critical COVID-19 patient diagnostics dynamic epitope Epitopes help high mortality high mortality rate humoral immune response Humoral immunity identify IgG antibodies IgG antibody IgM and IgG IgM antibodies IgM antibody immunogenic independent Infectious diseases innate immune response longitudinal analysis Microarray non-structural protein nonstructural protein nonstructural proteins Nsp3 Nsps nucleocapsid ORF3a Patient patients peptide peptide-based performed polyprotein Prognosis Proteases Protein respiratory SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 protein SARS-CoV-2 proteins SARS-CoV-2 proteome SARS-CoV-2 replication serum serum sample serum samples severe acute respiratory syndrome Coronavirus severity spike structural protein structural proteins survival therapy Transcription Treatment with COVID-19
[DOI] 10.1038/s41392-021-00718-w PMC 바로가기 [Article Type] Article

Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19

Research

Published on 2021-08-162022-10-29
Journal: Thrombosis Journal [Category] COVID-19,

[키워드] Admission Analysis analyzed Biomarker Care center city classification Clinical data Coronavirus disease 2019 Course COVID-19 COVID-19 patient Critical critical COVID-19 patient critical COVID-19 patients CRP level ELISA endothelial endothelial injury Factor FIVE glycocalyx high mortality intensive care laboratory data LDH no significant difference pathogenesis of COVID-19 Platelet required Result selected severe COVID-19 severe COVID-19 patient severe respiratory failure severity severity of COVID-19 significant difference significantly significantly higher SOFA score Syndecan-1 Temporal therapeutic target two groups university Yokohama
[DOI] 10.1186/s12959-021-00308-4 PMC 바로가기 [Article Type] Research

Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality

COVID-19 심각도 및 병원 내 사망률에 대한 예후 마커로서 아나필라톡신 및 염증성 사이토카인 보완

Immunology

Published on 2021-07-012022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 바이오마커,

[키워드] Activation Analysis anaphylatoxin anaphylatoxins C3a C5a changes in chemokine chemokines clinical disease clinical outcomes complement complement anaphylatoxins Complement pathway complement system complications COVID-19 COVID-19 patient COVID-19 severity Critical critical COVID-19 patient critical COVID-19 patients critical patients cytokine Cytokine storm Cytokines deaths dysregulation enrolled enzyme-linked immunosorbent enzyme-linked immunosorbent assay healthy control healthy controls highlight Hospitalization IgM antibody IgM antibody levels IL-1β IL-6 IL-8 immunopathology In-hospital in-hospital mortality infected with SARS-CoV-2 Inflammatory cytokine Inflammatory cytokines Inflammatory mediators Innate immunity Interaction interleukin investigated mediators mild cases mild COVID-19 patients mild patient mild patients Mortality Necrosis outcome Patient patients patients with COVID-19 positively correlated Potential treatment Prognosis prognostic properdin Protein RANTES SARS-COV-2 infection SARS-CoV-2 infections SARS‐CoV‐2 SARS‐CoV‐2 sera serum severe SARS Signaling significantly significantly higher survival group target Treatment strategies treatment strategy Tumor tumor necrosis tumor necrosis factor upregulated utility were measured
[DOI] 10.3389/fimmu.2021.668725 PMC 바로가기 [Article Type] Immunology

Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients

강력한 SARS-CoV-2-특이적 T 세포 면역 및 낮은 아나필라톡신 수치는 COVID-19 환자의 경증 질병 진행과 상관관계가 있습니다

Immunology

Published on 2021-06-142022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료법,

[키워드] addition analyzed anaphylatoxin anaphylatoxin C3a Antibody titer Antibody titers Blood C5a caused CD4 CD8 cellular characterized clearance Complete coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient Critical critical COVID-19 patient disease severity elevated ELISA ELISPOT ELISpot assay evaluated flow cytometry healthy individual highest humoral immune response IFNγ IgG immune complex immune responses immunodominant indicate infected individuals Level Lymphocytes lymphopenia Mild mild infections mononuclear cell mononuclear cells Mortality neutralization ability neutralizing Abs Neutralizing activity nucleocapsid Patient patients peptide peptide pool peripheral Peripheral blood Peripheral blood mononuclear cells potent reduced respiratory Respiratory system robust SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2-infected individuals SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody severe disease progression significantly specific antibodies Spike proteins T cell T cell immunity T cell response T cell responses T cells T lymphocyte Viral viral infection viral infections
[DOI] 10.3389/fimmu.2021.684014 PMC 바로가기 [Article Type] Immunology

Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial

Research article

Published on 2021-06-052022-10-05
Journal: EClinicalMedicine [Category] 바이오마커, 치료법,

[키워드] 28-day mortality 95% CI adverse event age analysed Anti-COVID-19 Immunoglobulin Anti-SARS COV-2 antibody ARDS Arm Biomarker C-IVIG chest X-ray clinical status Commission complete recovery conducted consequence control group convalescent plasma COVID-19 Critical critical COVID-19 critical COVID-19 patient Critically ill Cytokine storm discharged Disease progression dosage education enrolled expected finding follow-up period funding groups HEC Horowitz Hyper-Immune IVIG infected individuals intention-to-treat population Intervention intervention arm intervention group IQR Karachi life-threatening Lung injury median occurred outcome parallel-group participant passive immunization Patient Randomized randomized clinical trial receiving reduced Registered reported respiratory risk risk reduction Safe Sepsis severe COVID-19 significantly single center Standard of care survival therapy Treatment Trial university virus
[DOI] 10.1016/j.eclinm.2021.100926 [Article Type] Research article

Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patients

Article

Published on 2021-06-042022-10-04
Journal: Scientific Reports [Category] MERS, SARS, 바이오마커, 임상, 진단, 치료기술, 치료법,